To see the effect of magnesium in eye block

Effect of addition of magnesium to 0.75% ropivacaine for peribulbar block: A prospective randomized double blind study

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/08/003884

Enrollment

Registered

2013-08-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients with eye disease requiring eye surgery

Interventions

Intervention1: Magnesium Sulphate: Magnesium is physiological calcium antagonist and competitive N- methyl- D- aspartate (NMDA) receptor antagonist. It has been found that when magnesium sulphate is a

Eligibility

Inclusion criteria

Inclusion criteria: All ASA I to III patients, aged > 18 yr to <75 years, undergoing ophthalmic surgery under peribulbar block.

Exclusion criteria

Exclusion criteria: i. Refusal to participate by patient ii. Mental retardation iv. History of bleeding disorder v. Allergy to ropivacaine & hyluronidase

Design outcomes

Primary

Measure	Time frame
1. To evaluate the effect of addition of magnesium sulphate to 0.75% ropivacaine on the time for onset of akinesia of the globe and duration of analgesia, for peribulbar anaesthesia in ophthalmic surgeries.Timepoint: from the start of injection through peribulbar route till the end of surgery (20 minutes to 2 hours) and for duration of analgesia and complications till 24 hours after injection of peribulbar block	—

Measure

Time frame

1. To evaluate the effect of addition of magnesium sulphate to 0.75% ropivacaine on the time for onset of akinesia of the globe and duration of analgesia, for peribulbar anaesthesia in ophthalmic surgeries.Timepoint: from the start of injection through peribulbar route till the end of surgery (20 minutes to 2 hours) and for duration of analgesia and complications till 24 hours after injection of peribulbar block

—

Secondary

Measure	Time frame
noneTimepoint: not applecable	—

Countries

India

Contacts

Public ContactRenu Sinha

All India Institute of Medical Sciences, New Delhi

renuagarwal4@rediffmail.com9868397822

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026